Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction by jonadmin | Sep 29, 2022 | Uncategorized
Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer by jonadmin | May 25, 2022 | Uncategorized
Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases by jonadmin | Mar 8, 2022 | Uncategorized
Recent Comments